123 related articles for article (PubMed ID: 38295753)
41. Inhibition of IGFBP-2 improves the sensitivity of bladder cancer cells to cisplatin via upregulating the expression of maspin.
Zhu H; Yun F; Shi X; Wang D
Int J Mol Med; 2015 Aug; 36(2):595-601. PubMed ID: 26080829
[TBL] [Abstract][Full Text] [Related]
42. MAFG-AS1/MAFG positive feedback loop contributes to cisplatin resistance in bladder urothelial carcinoma through antagonistic ferroptosis.
Xiang L; Zeng Q; Liu J; Xiao M; He D; Zhang Q; Xie D; Deng M; Zhu Y; Liu Y; Bo H; Liu X; Zhou M; Xiong W; Zhou Y; Zhou J; Li X; Cao K
Sci Bull (Beijing); 2021 Sep; 66(17):1773-1788. PubMed ID: 36654385
[TBL] [Abstract][Full Text] [Related]
43. LncRNA MST1P2/miR-133b axis affects the chemoresistance of bladder cancer to cisplatin-based therapy via Sirt1/p53 signaling.
Chen J; Li Y; Li Z; Cao L
J Biochem Mol Toxicol; 2020 Apr; 34(4):e22452. PubMed ID: 32052927
[TBL] [Abstract][Full Text] [Related]
44. The Role of Pyruvate Dehydrogenase Kinase-4 (PDK4) in Bladder Cancer and Chemoresistance.
Woolbright BL; Choudhary D; Mikhalyuk A; Trammel C; Shanmugam S; Abbott E; Pilbeam CC; Taylor JA
Mol Cancer Ther; 2018 Sep; 17(9):2004-2012. PubMed ID: 29907593
[TBL] [Abstract][Full Text] [Related]
45.
Wei W; Sun J; Zhang H; Xiao X; Huang C; Wang L; Zhong H; Jiang Y; Zhang X; Jiang G
Cancer Res; 2021 Dec; 81(24):6142-6156. PubMed ID: 34702726
[TBL] [Abstract][Full Text] [Related]
46. Biased Expression of the FOXP3Δ3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance.
Zhang H; Prado K; Zhang KX; Peek EM; Lee J; Wang X; Huang J; Li G; Pellegrini M; Chin AI
Clin Cancer Res; 2016 Nov; 22(21):5349-5361. PubMed ID: 27189164
[TBL] [Abstract][Full Text] [Related]
47. PBX1 Participates in Estrogen-mediated Bladder Cancer Progression and Chemo-resistance Affecting Estrogen Receptors.
Zhao Y; Che J; Tian A; Zhang G; Xu Y; Li S; Liu S; Wan Y
Curr Cancer Drug Targets; 2022; 22(9):757-770. PubMed ID: 35422219
[TBL] [Abstract][Full Text] [Related]
48. Suberoylanilide Hydroxamic Acid Can Re-sensitize a Cisplatin-Resistant Human Bladder Cancer.
Ryu H; Jin H; Ho JN; Bae J; Lee E; Lee SE; Lee S
Biol Pharm Bull; 2019; 42(1):66-72. PubMed ID: 30606990
[TBL] [Abstract][Full Text] [Related]
49. NPEPPS Is a Druggable Driver of Platinum Resistance.
Jones RT; Scholtes M; Goodspeed A; Akbarzadeh M; Mohapatra S; Feldman LE; Vekony H; Jean A; Tilton CB; Orman MV; Romal S; Deiter C; Kan TW; Xander N; Araki SP; Joshi M; Javaid M; Clambey ET; Layer R; Laajala TD; Parker SJ; Mahmoudi T; Zuiverloon TCM; Theodorescu D; Costello JC
Cancer Res; 2024 May; 84(10):1699-1718. PubMed ID: 38535994
[TBL] [Abstract][Full Text] [Related]
50. Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.
Wei L; Chintala S; Ciamporcero E; Ramakrishnan S; Elbanna M; Wang J; Hu Q; Glenn ST; Murakami M; Liu L; Gomez EC; Sun Y; Conroy J; Miles KM; Malathi K; Ramaiah S; Anbarasu A; Woloszynska-Read A; Johnson CS; Conroy J; Liu S; Morrison CD; Pili R
Oncotarget; 2016 Nov; 7(47):76374-76389. PubMed ID: 27823983
[TBL] [Abstract][Full Text] [Related]
51. NAT10 Drives Cisplatin Chemoresistance by Enhancing ac4C-Associated DNA Repair in Bladder Cancer.
Xie R; Cheng L; Huang M; Huang L; Chen Z; Zhang Q; Li H; Lu J; Wang H; Zhou Q; Huang J; Chen X; Lin T
Cancer Res; 2023 May; 83(10):1666-1683. PubMed ID: 36939377
[TBL] [Abstract][Full Text] [Related]
52. Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy.
Taniyama D; Sakamoto N; Takashima T; Takeda M; Pham QT; Ukai S; Maruyama R; Harada K; Babasaki T; Sekino Y; Hayashi T; Sentani K; Pommier Y; Murai J; Yasui W
Cancer Sci; 2022 Feb; 113(2):784-795. PubMed ID: 34808009
[TBL] [Abstract][Full Text] [Related]
53. Role of the MUC1-C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma.
Shigeta K; Hasegawa M; Kikuchi E; Yasumizu Y; Kosaka T; Mizuno R; Mikami S; Miyajima A; Kufe D; Oya M
Cancer Sci; 2020 Oct; 111(10):3639-3652. PubMed ID: 32677159
[TBL] [Abstract][Full Text] [Related]
54. Characterization and treatment of gemcitabine- and cisplatin-resistant bladder cancer cells with a pan-RAS inhibitor.
Yoshino H; Yokoyama S; Tamai M; Okamura S; Iizasa S; Sakaguchi T; Osako Y; Inoguchi S; Matsushita R; Yamada Y; Nakagawa M; Tatarano S; Tanimoto A; Enokida H
FEBS Open Bio; 2023 Jun; 13(6):1056-1066. PubMed ID: 37079001
[TBL] [Abstract][Full Text] [Related]
55. Targeting an Autocrine Regulatory Loop in Cancer Stem-like Cells Impairs the Progression and Chemotherapy Resistance of Bladder Cancer.
Wang KJ; Wang C; Dai LH; Yang J; Huang H; Ma XJ; Zhou Z; Yang ZY; Xu WD; Hua MM; Lu X; Zeng SX; Wang HQ; Zhang ZS; Cheng YQ; Liu D; Tian QQ; Sun YH; Xu CL
Clin Cancer Res; 2019 Feb; 25(3):1070-1086. PubMed ID: 30397177
[TBL] [Abstract][Full Text] [Related]
56. CAB39 promotes cisplatin resistance in bladder cancer via the LKB1-AMPK-LC3 pathway.
Gao D; Wang R; Gong Y; Yu X; Niu Q; Yang E; Fan G; Ma J; Chen C; Tao Y; Lu J; Wang Z
Free Radic Biol Med; 2023 Nov; 208():587-601. PubMed ID: 37726090
[TBL] [Abstract][Full Text] [Related]
57. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
[TBL] [Abstract][Full Text] [Related]
58. GABBR2 as a Downstream Effector of the Androgen Receptor Induces Cisplatin Resistance in Bladder Cancer.
Elahi Najafi MA; Yasui M; Teramoto Y; Tatenuma T; Jiang G; Miyamoto H
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762034
[TBL] [Abstract][Full Text] [Related]
59. Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression.
Daga M; Pizzimenti S; Dianzani C; Cucci MA; Cavalli R; Grattarola M; Ferrara B; Scariot V; Trotta F; Barrera G
Phytomedicine; 2019 Mar; 56():156-164. PubMed ID: 30668336
[TBL] [Abstract][Full Text] [Related]
60. LncRNA-MALAT1 mediates cisplatin resistance via miR-101-3p/VEGF-C pathway in bladder cancer.
Liu P; Li X; Cui Y; Chen J; Li C; Li Q; Li H; Zhang X; Zu X
Acta Biochim Biophys Sin (Shanghai); 2019 Nov; 51(11):1148-1157. PubMed ID: 31650173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
